Paxos Therapeutics

Paxos Therapeutics

<table class="infobox infobox-company">
<tr>
<th class="infobox-header" colspan="2">Paxos Therapeutics</th>
</tr>
<tr>
<td class="label">Type</td>
<td>Biotechnology Company</td>
</tr>
<tr>
<td class="label">Focus</td>
<td>Neurodegeneration</td>
</tr>
</table>

Overview

Paxos Therapeutics is a private biotechnology company founded in the 2020s and headquartered in the United States, focused on developing novel therapeutic interventions for age-related neurodegenerative diseases. The company operates within the broader landscape of neurodegeneration research, targeting molecular pathways implicated in cognitive decline and neuronal dysfunction. Paxos Therapeutics distinguishes itself by focusing on foundational aging biology and the intersection of cellular senescence, neuroinflammation, and neurodegeneration, rather than pursuing traditional target-by-target approaches common in neurodegenerative disease drug development.

Function and Biology

Paxos Therapeutics

<table class="infobox infobox-company">
<tr>
<th class="infobox-header" colspan="2">Paxos Therapeutics</th>
</tr>
<tr>
<td class="label">Type</td>
<td>Biotechnology Company</td>
</tr>
<tr>
<td class="label">Focus</td>
<td>Neurodegeneration</td>
</tr>
</table>

Overview

Paxos Therapeutics is a private biotechnology company founded in the 2020s and headquartered in the United States, focused on developing novel therapeutic interventions for age-related neurodegenerative diseases. The company operates within the broader landscape of neurodegeneration research, targeting molecular pathways implicated in cognitive decline and neuronal dysfunction. Paxos Therapeutics distinguishes itself by focusing on foundational aging biology and the intersection of cellular senescence, neuroinflammation, and neurodegeneration, rather than pursuing traditional target-by-target approaches common in neurodegenerative disease drug development.

Function and Biology

The company's research platform centers on understanding how fundamental aging processes contribute to neurological dysfunction and disease. Paxos Therapeutics investigates the role of cellular senescence—the process by which cells permanently cease division while remaining metabolically active—as a driver of age-related neurological decline. By studying senescent cell accumulation in the brain and peripheral tissues, the company aims to identify therapeutic opportunities to either eliminate senescent cells or neutralize their harmful effects on neighboring neural tissues.

A key aspect of Paxos' biological focus involves sirtuins, a family of NAD-dependent deacetylases and ADP-ribosyltransferases that regulate cellular stress responses, metabolism, and longevity. The SIRT6 protein, in particular, plays critical roles in maintaining genomic stability, regulating inflammation, and modulating mitochondrial function—all processes relevant to neuronal survival and cognitive preservation. By targeting sirtuins and related pathways, Paxos explores how enhancing cellular stress-response mechanisms might protect against age-related cognitive decline.

Role in Neurodegeneration

Neuroinflammation—chronic, low-grade inflammation within the central nervous system—represents a hallmark feature of multiple neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and other age-related cognitive disorders. Paxos Therapeutics recognizes that senescent cells and dysfunctional cellular stress responses contribute substantially to neuroinflammatory states. These processes involve microglial activation, astrocytic dysfunction, and the release of pro-inflammatory cytokines including IL-6, TNF-α, and IL-1β.

The company's approach addresses neurodegeneration by targeting upstream biological drivers rather than focusing exclusively on disease-specific proteins like amyloid-β or tau. This strategy reflects emerging evidence that age-related cognitive decline involves shared mechanisms across different neurodegenerative diseases, suggesting that interventions targeting fundamental aging pathways might benefit multiple indications.

Molecular Mechanisms

Paxos Therapeutics' therapeutic development likely focuses on several interconnected mechanisms. SIRT6 activation enhances DNA repair capacity, suppresses nuclear factor-kappa B (NF-κB) signaling—a central regulator of inflammatory responses—and improves mitochondrial biogenesis and function. These effects collectively reduce neuroinflammation and support neuronal metabolic health.

Additionally, strategies to eliminate senescent cells or block their paracrine effects address the senescence-associated secretory phenotype (SASP), wherein senescent cells release numerous pro-inflammatory and pro-degradative molecules that damage surrounding tissues. Therapeutic interventions targeting senescent cell burden or SASP in neural tissue could reduce chronic neuroinflammation and preserve cognitive function.

NAD metabolism represents another mechanistic focus, as NAD availability declines with age and restoration of NAD levels enhances sirtuin function and mitochondrial health. Therapeutic approaches enhancing NAD bioavailability or directly activating sirtuins could improve neuronal resilience.

Clinical and Research Significance

Paxos Therapeutics' approach addresses a critical gap in neurodegeneration therapeutics: most approved disease-modifying treatments target late-stage pathology in individual diseases, offering limited benefit for age-related cognitive decline more broadly. By focusing on fundamental aging mechanisms, Paxos pursues potentially disease-modifying interventions applicable across multiple neurodegenerative conditions. Such an approach could translate to therapeutics for Alzheimer's disease, Parkinson's disease, and age-related cognitive impairment.

Related Entities

Paxos Therapeutics operates within the broader ecosystem of aging biology and neurodegeneration research, engaging with academic institutions studying cellular senescence and sirtuins, as well as other biotechnology companies targeting aging pathways. The company's scientific direction aligns with emerging consensus regarding geroscience—the intersection of aging research and disease biology—and the recognition that modulating fundamental aging processes may provide broad neuroprotection.